ReportWire

Tag: National Institutes of Health (NIH)

  • Rutgers Researchers to Study the Impact of Multiple Health Conditions on Medication Outcomes in Older Adults

    Rutgers Researchers to Study the Impact of Multiple Health Conditions on Medication Outcomes in Older Adults

    [ad_1]

    Newswise — The National Institutes of Health has awarded Rutgers a $3.5 million grant to conduct a five-year study exploring the impact medications have on older adults with multiple medical conditions.

    The goal of researchers from Rutgers Center for Pharmacoepidemiology and Treatment Science (PETS) is to provide patients with multiple chronic conditions, caregivers and health care providers with information needed to make informed treatment decisions.

    “Unfortunately, most clinical trials of medications do not include patients with multimorbidity, which means that there is little data available about the risks and benefits of medications in this population,” said Chintan Dave, assistant director at PETS and the principal investigator of the National Heart, Lung and Blood Institute grant-backed project. “This lack of information makes it difficult for health care providers to make informed decisions about treating patients with multiple medical conditions.”

    Multimorbidity is a common issue for older adults, according to researchers. In the U.S., more than two thirds of adults over the age of 65 have multiple chronic conditions, which can lead to higher health care costs and increased risk of negative health outcomes, including death.

    “With over 36 million older adults in the U.S. affected by multimorbidity, this is a pressing issue that requires immediate attention,” said Dave, who also is a core faculty member of the Rutgers Institute for Health, Health Care Policy and Aging Research (IFH) and an assistant professor with Rutgers Ernest Mario School of Pharmacy.

    Dave and his colleagues will use data from more than 23 million patients to learn how having multiple conditions affects the benefits and risks of medications, representing the first effort to systematically evaluate the impact of multimorbidity on medication related outcomes. Specifically, researchers will examine medication use and outcomes in three highly prevalent chronic conditions: Type 2 diabetes, atrial fibrillation and atherosclerotic cardiovascular disease.

    Coinvestigators involved in the study include Brian Strom, the chancellor of Rutgers Biomedical and Health Sciences; Tobias Gerhard, interim director of IFH and director of PETS; Jason Roy, a professor of biostatistics and chair of the Department of Biostatistics and Epidemiology at the Rutgers School of Public Health; Soko Setoguchi, a core faculty member at PETS and IFH, professor of medicine at Rutgers Robert Wood Johnson Medical School and professor of epidemiology at Rutgers School of Public Health; and Melissa Wei, an assistant professor of medicine in residence at the David Geffen School of Medicine at University of California, Los Angeles.

    The grant was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health under Award Number R01HL163163. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    [ad_2]

    Rutgers University-New Brunswick

    Source link

  • Making engineered cells dance to ultrasound

    Making engineered cells dance to ultrasound

    [ad_1]

    Newswise — Let’s say you needed to move an individual cell from one place to another. How would you do it? Maybe some special tweezers? A really tiny shovel?

    The fact is that manipulating individual cells is a difficult task. Some work has been done on so-called optical tweezers that can push cells around with beams of light, but while they are good at moving a single cell around, they are not intended for manipulating larger numbers of cells.

    New research conducted at Caltech has created an alternative: air-filled proteins, produced by genetically engineered cells, that can be pushed around—along with the cells containing them—by ultrasound waves. A paper describing the work appears in the journal Science Advances.

    The work builds on previous work conducted in the lab of Mikhail Shapiro, professor of chemical engineering and medical engineering and investigator with the Howard Hughes Medical Institute.

    Shapiro has for years worked with gas vesicles derived from bacteria as an acoustic tag. These vesicles, which are air-filled capsules of protein, provide buoyancy to some species of aquatic bacteria. But they also have another useful quality: Because of their air-filled interiors, they show up quite strongly in ultrasound imagery. Shapiro’s discovery of this quality has led his lab to develop gas vesicles as a genetic marker for tracking the location of individual bacterial cells, and for observing gene-expression activity in mammalian cells deep inside the body.

    Now, Shapiro and his colleagues have shown that these vesicles can push and pull cells into specific locations under the influence of ultrasound. The phenomenon is very similar to how ultrasound in air can be used to suspend and/or move small, light objects. This is due to the fact that sound waves create pressure zones that act on objects in their vicinity. The physical properties of an object or material determine whether it will be attracted to a high-pressure zone or repulsed by it. Normal cells are pushed away from areas of higher pressure, but cells containing gas vesicles are attracted to them.

    “We’ve used these vesicles for imaging previously, and this time we’ve shown that we can actually use them as actuators so we can apply force to these objects using ultrasound,” says Di Wu (MS ’16, PhD ’21), a research scientist in Shapiro’s lab and the study’s lead author. “What this allows us to do is to move cells around in space using ultrasound and to be able to do so in a very selective manner.”

    Shapiro and Wu say there a few reasons you might want to be able to move cells around. For one, tissue engineering—the creation of artificial tissues for research or medical purposes—requires cells of specific types to be arranged in complex patterns. An artificial muscle might need multiple layers of muscle cells, cells that create tendons, and nerve cells, for example.

    Another case in which you might want to move cells around is in cell-based therapy, a field of medicine in which cells with desirable properties are introduced into the body.

    “You’re introducing engineered cells into the body, and they go all over the place to find their target,” Di says. “But with this technology, we potentially have a way to guide them to the desired location into the body.”

    As a demonstration, the team showed that cells containing gas vesicles can be forced to clump into a small ball, or arranged as thin bands, or pushed to the edges of a container. When they changed the ultrasound pattern, the cells “danced” to take up new positions. They also developed an ultrasound pattern that pushed the cells into the shape of the letter “R” in a gel that held them in that shape after it solidified. They call the resulting figure an “acoustic hologram.”

    Wu says one area where their research has the potential for immediate impact is in cell sorting, a process necessary for various kinds of biological and medical research.

    “A common way people sort cells now is to engineer them to express a fluorescent protein and then use a fluorescent-activated cell sorter (FACS),” he says. “That is a $300,000 piece of equipment that is bulky, often lives in a biosafety cabinet, and doesn’t sort cells very fast.”

    “In contrast, acousto-fluidic sorting can be done with a tiny little chip that costs maybe $10. The reason for this difference is that in fluorescent sorting, you have to separately measure the gene expression of the cells and then move them. This is done one cell at a time. With gas vesicle expression, the cell’s genetics are directly linked to the force that’s being applied to the cell. If they express gas vesicles, they will experience a different force, so we don’t need to separately check if they’re expressing gas vesicles and then move them; we can move them all at once. That greatly simplifies things.”

    The paper describing the research, titled “Biomolecular actuators for genetically selective acoustic manipulation of cells,” appears in the February 22 of Science Advances. Additional co-authors are former Caltech medical engineering PhD students Colin Cook (MS ’16, PhD ’19), who is now a staff scientist at City of Hope; and David R. Mittelstein (MS ’16, PhD ’20), who is now a resident physician at Scripps Health; former postdoctoral fellow David Maresca, who is now an assistant professor at Delft University of Technology, Netherlands; Caltech chemical engineering graduate student Maria Abundo and bioengineering graduate students Mengtong Duan, Justin Lee, and Shirin Shivaei; Dina Malounda of the Howard Hughes Medical Institute, Diego Baresch of the University of Bordeaux in France; Zhichao Ma of the Max Planck Institute for Intelligent Systems in Stuttgart, Germany; Tian Qiu of the University of Stuttgart, Germany; and Peer Fischer of the Max Planck Institute for Medical Research and Heidelberg University in Heidelberg, Germany.

    Funding for the research was provided by the National Institutes of Health, the U.S. Army’s Institute for Collaborative Biotechnologies, the David and Lucile Packard Foundation, and the Pew Charitable Trust. Mikhail Shapiro is an affiliated faculty member with the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech.

    [ad_2]

    California Institute of Technology

    Source link

  • Daily rhythm detected for cerebral blood flow in stroke patients

    Daily rhythm detected for cerebral blood flow in stroke patients

    [ad_1]

    Newswise — Strokes are a leading cause of morbidity and mortality in the United States, as well as around the world. Various environmental and biological factors are known to affect the risks and outcomes of strokes. A new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, analyzed the cerebral blood flow (CBF) regulation of individuals who had experienced strokes. The team found that cerebral autoregulation (CA) — one of the key processes to maintain sufficient blood supply to the brain — displayed a daily rhythm in stroke patients, with more degraded regulation during nighttime and morning hours, as compared to that in the afternoon hours. Their results, which are published in the Journal of Cerebral Blood Flow and Metabolismare relevant for health care planning during stroke recovery.

    “The care and course of actions done after a stroke are essential for optimal rehabilitation. Our study suggests that the daily rhythm of CBF regulation in stroke patients may be highly relevant to managing an individual’s activity and stroke recovery,” said senior author, Kun Hu, PhD, of the Medical Biodynamics Program in the Brigham’s Division of Sleep and Circadian Disorders. “Exercise and surgery post-stroke could be more optimal when scheduled during afternoon hours, as this is when dynamic CA functions more effectively. These results may improve our understanding of a vulnerable time window for the cerebrovascular system and help guide daily activity and personal care during stroke recovery, which could improve health outcomes for patients who have had a stroke.”

    Stable CBF is a necessary component for normal brain function. Dramatic changes in CBF can cause increased cranial pressure and brain tissue damage. Thus, a process like CA, which helps maintain relatively stable CBF through constriction and dilation of blood vessels in the brain, particularly during changes in an individual’s blood pressure (BP), is crucial. Currently, there is a gap in knowledge concerning the daily variance of CA in stroke patients. Generally, the daily rhythms of physiological functions can be controlled by external behaviors like food intake, sleep, and exercise, as well as the internal circadian clock. This study is among the first to examine the potential variation of CA in the stroke population.

    The research team observationally studied 28 participants being treated in a hospital in São Paulo, Brazil after experiencing a stroke. They received thrombolysis within 5 hours of the onset of their symptoms. After undergoing this procedure, the participants’ CA was assessed over the course of 48 hours at various time points by examining the relationship between temporal changes in blood pressure and cerebral blood flow velocity of the middle cerebral artery.

    Analysis of the results showed evidence of differing cerebral blood flow regulation during various times of the day, especially when cerebral blood flow and pressure fluctuated at large time scales or low frequencies < 0.05 Hz. In particular, a more degraded regulation motif was seen during the nighttime and morning hours when compared to the afternoon. This dysregulation interval coincides with the increased prevalence of recurrent and first-ever stroke events during morning times.

    While these results are promising, the researchers identified future avenues to assist in creating a greater understanding of the regulation mechanism.

    “Interestingly, the daily rhythm of CA was present in both stroke and non-stroke sides of the brain, suggesting the factor(s) driving the rhythm should affect CBF regulation globally,” said first author Daniel Abadjiev, of the Medical Biodynamics Program in the Brigham’s Division of Sleep and Circadian Disorders. “To better understand underlying mechanisms, future studies should consider more frequent assessments across the 24-hour cycle, an increase in patient sample size, inclusion of non-stroke controls, and monitoring of the daily activity rhythms like sleep and exercise as well as intrinsic circadian rhythm among the participants.”

    “This study demonstrates that a daily rhythm does exist for stroke patients,” said Hu. “Rehab plans should look to identify the daily rhythm and design a strategy that makes use of optimal CA. The long-term goal is to see if we can further control the rhythm of CA by manipulating an individual’s daily behavioral cycles or endogenous circadian clock in order to deliver more personalized medicine and improve their recovery.”

    Disclosures: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

    Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: KH was partially supported by the National Institutes of Health grants (RF1AG059867 and RF1AG064312). ET-D was supported by the São Paulo Research Foundation (FAPESP, # 2021/03076-4) and by the National Council for Scientific and Technological Development (CNPq, # 307434/2021-4).

    Paper Cited: Abadjiev, D et al. “Daily rhythm of dynamic cerebral autoregulation in patients after stroke”. Journal of Cerebral Blood Flow & Metabolism. DOI: 10.1177/0271678X231153750.

    [ad_2]

    Brigham and Women’s Hospital

    Source link

  • Receptor location matters for psychedelic drug effects

    Receptor location matters for psychedelic drug effects

    [ad_1]

    Newswise — Location, location, location is the key for psychedelic drugs that could treat mental illness by rapidly rebuilding connections between nerve cells. In a paper published Feb. 17 in Science, researchers at the University of California, Davis show that engaging serotonin 2A receptors inside neurons promotes growth of new connections but engaging the same receptor on the surface of nerve cells does not. 

    The findings will help guide efforts to discover new drugs for depression, PTSD and other disorders, said senior author David E. Olson, associate professor of chemistry, biochemistry and molecular medicine and director of the Institute for Psychedelics and Neurotherapeutics at UC Davis. 

    Drugs such as LSD, MDMA and psilocybin show great promise for treating a wide range of mental disorders that are characterized by a loss of neural connections. In laboratory studies, a single dose of these drugs can cause rapid growth of new dendrites – branches – from nerve cells, and formation of new spines on those dendrites. 

    Olson calls this group of drugs “psychoplastogens” because of their ability to regrow and remodel connections in the brain. 

    Earlier work from Olson’s and other labs showed that psychedelic drugs work by engaging the serotonin 2A receptor (5-HT2AR). But other drugs that engage the same receptor, including serotonin, do not have the same growth effects. 

    Maxemiliano Vargas, a graduate student in Olson’s lab, Olson and colleagues experimented with chemically tweaking drugs and using transporters to make it easier or harder for compounds to slip across cell membranes. Serotonin itself is polar, meaning it dissolves well in water but does not easily cross the lipid membranes that surround cells. The psychedelics, on the other hand, are much less polar and can easily enter the interior of a cell. 

    They found that the growth-promoting ability of compounds was correlated with the ability to cross cell membranes. 

    Drug receptors are usually thought of as being on the cell membrane, facing out. But the researchers found that in nerve cells, serotonin 2A receptors were concentrated inside cells, mostly around a structure called the Golgi body, with some receptors on the cell surface. Other types of signaling receptors in the same class were on the surface. 

    The results show that there is a location bias in how these drugs work, Olson said. Engaging the serotonin 2A receptor when it is inside a cell produces a different effect from triggering it when it is on the outside. 

    “It gives us deeper mechanistic insight into how the receptor promotes plasticity, and allows us to design better drugs,” Olson said. 

    Additional authors on the paper include: from UC Davis, Lee Dunlap, Chunyang Dong, Samuel Carter, Robert Tombari, Lin Tian, John Gray, Shekib Jami, Seona Patel, Lindsay Cameron and Hannah Saeger; Joseph Hennessey and John McCorvy from the Medical College of Wisconsin, Milwaukee. The work was supported by grants from the National Institutes of Health and the Camille and Henry Dreyfus Foundation, and by a sponsored research agreement with Delix Therapeutics. 

    [ad_2]

    University of California, Davis

    Source link

  • Discovery could lead to new fungicides to protect rice crops

    Discovery could lead to new fungicides to protect rice crops

    [ad_1]

    Newswise — A fungus that plagues rice crops worldwide gains entry to plant cells in a way that leaves it vulnerable to simple chemical blockers, a discovery that could lead to new fungicides to reduce the substantial annual losses of rice and other valuable cereals.

    Each year, blast disease, caused by the fungal pathogen Magnaporthe oryzae, attacks and kills plants that represent between 10% and 35% of the global rice crop, depending on weather conditions.

    University of California, Berkeley, biochemists led by Michael Marletta, professor of chemistry and of molecular and cell biology, discovered that the fungus secretes an enzyme that punches holes in the tough outer layer of rice leaves. Once inside, the fungus rapidly grows and inevitably kills the plant.

    In a paper published this week in the journal Proceedings of the National Academy of Sciences, Marletta and his colleagues describe the structure of the enzyme and how it works to help the fungus invade plants. Because the enzyme is secreted onto the surface of the rice leaf, a simple spray could be effective in destroying the enzyme’s ability to digest the wall of the plant. The scientists are now screening chemicals to find ones that block the enzyme.

    “The estimates are that if you could knock out this fungus, you could feed 60 million more people in the world,” said Marletta, the Choh Hao and Annie Li Chair in the Molecular Biology of Diseases at UC Berkeley. “This enzyme is a unique target. Our hope here is that we’ll screen to find some unique chemicals and spin out a company to develop inhibitors for this enzyme.”

    This target is one of a family of enzymes called polysaccharide monooxygenases (PMO) that Marletta and his UC Berkeley colleagues discovered a little over 10 years ago in another, more widespread fungus, Neurospora. Polysaccharides are sugar polymers that include starch as well as the tough fibers that make plants sturdy, including cellulose and lignin. The PMO enzyme breaks cellulose into smaller pieces, making the polysaccharide susceptible to other enzymes, such as cellulases, and speeding up the breakdown of plant fibers.

    “There is an urgent need for more sustainable control strategies for rice blast disease, particularly in South Asia and sub-Saharan Africa,” said Nicholas Talbot, who is Marletta’s colleague and co-author, a plant disease expert and executive director of The Sainsbury Laboratory in Norwich in the United Kingdom. “Given the importance of the polysaccharide monooxygenase to plant infection, it may be a valuable target for developing new chemistries that could be applied at much lower doses than existing fungicides and with less potential environmental impact. It might also be a target for completely chemical-free approaches, too, such as gene silencing.”

    Marletta and UC Berkeley Ph.D students Will Beeson and Chris Phillips were originally interested in these enzymes because they degrade plant cellulose much more quickly than other previously described enzymes and thus had potential to turn biomass into sugar polymers that can be fermented more readily into biofuels. Fungi use PMOs to provide a source of food.

    He and UC Berkeley colleagues subsequently found hints that some fungal PMOs may do more than merely turn cellulose into food. These PMOs were turned on in the early stages of infection, implying that they’re important in the infection process rather than providing food.

    That’s what Marletta, Talbot and their colleagues found. Led by postdoctoral fellow Alejandra Martinez-D’Alto, the UC Berkeley scientists biochemically characterized this unique PMO, called MoPMO9A, while Talbot and UC Berkeley postdoctoral fellow Xia Yan showed that knocking out the enzyme reduced infection in rice plants.

    Marletta and his UC Berkeley colleagues have found similar PMOs in fungi that attack grapes, tomatoes, lettuce and other major crops, which means the new findings may have broad application against plant fungal diseases.

    “It isn’t just rice that small molecule inhibitors could be used against. They could be widely used against a variety of different crop pathogens,” Marletta said. “I think the future for this, in terms of drug development for plant pathogens, is pretty exciting, which is why we are going to pursue both the fundamental science of it, like we always do, and try to put together pieces to spin it out as a company.”

    Biofuels lead way to attacking fungal pathogen

    Marletta specializes in identifying and studying new and unusual enzymes in human cells. But 10 years ago, when people got excited about biofuels as a way to address climate change, he was awarded a grant from UC Berkeley’s Energy Biosciences Institute to search for enzymes in other life forms that digest plant cellulose faster than the enzymes known at the time. The goal was to turn tough cellulose fibers into short-chain polysaccharides that yeast could ferment into fuel.

    “I said to two of my first-year graduate students, Chris Phillips and Will Beeson, ‘You know, there’s got to be organisms out there that eat cellulose fast,’” Marletta said. “Those are the ones we want to find, because we know the enzymes that eat it slow, and they’re not particularly useful in a biotechnology sense because they’re slow.”

    Phillips and Beeson succeeded in finding fast-acting enzymes in a common fungus, Neurospora, which is among the first fungi to attack dead trees after a fire and does a quick job of digesting wood for nutrients. They isolated the enzyme responsible, the first known PMO, and described how it worked. Since then, Marletta’s students have identified 16,000 varieties of PMO, most in fungi, but some in wood-eating bacteria. To date, these have had some success in speeding the production of biofuels as part of a cocktail of other enzymes, though they haven’t made biofuels competitive with other fuels.

    But Marletta was intrigued by a small subset of these 16,000 varieties that seemed to do more than provide nutrition for fungi. MoPMO9A, in particular, had an amino acid segment that binds to chitin, a polysaccharide that forms the outer coat of fungi, but is not found in rice. And though all PMOs are secreted, MoPMO9A was secreted during the infectious cycle of the fungus.

    Studies subsequently showed that Magnaporthe concentrates MoPMO9A in a pressurized infection cell, called the appressorium, from which it is secreted onto the plant, with one portion of the enzyme binding to the outside of the fungus. The other end of the enzyme has a copper atom embedded in its center. When the fungus slaps the loose end of the enzyme onto the rice leaf, the copper atom catalyzes a reaction with oxygen to break cellulose fibers, helping the fungus breach the leaf surface and invade the entire leaf.

    “We were curious: ‘Hey, why does this enzyme have a chitin-binding domain if it’s supposed to be working on cellulose?’” according to Marletta. “And that’s when we thought, ‘Well, maybe it’s secreted, but it sticks to the fungus. That way, when the fungus is sitting on the plant, it can have between it and the leaf the catalytic domain to punch the hole into the leaf.’”

    That proved to be the case. Marletta and Talbot are now testing other pathogens that produce PMOs to see if they use the same trick to enter and infect leaves. If so — Marletta is confident that they do — it opens avenues to attack them with a spray-on fungicide, as well.

    “The only place you find PMOs like this is in plant pathogens that have to gain access to their host. So, they’re almost certainly going to be working the same way,” Marletta said. “I think the scope of work to develop inhibitors to this particular PMO is going to be well beyond rice, even though that itself is pretty important. We’re going to be able to use them in other important crop plants.”

    Other co-authors of the paper are Alejandra Martinez-D’Alto, Tyler Detomasi, Richard Sayler and William Thomas of UC Berkeley. Marletta is a member of the Berkeley branch of the California Institute for Quantitative Biosciences (QB3). The research was funded by the National Science Foundation (CHE-1904540, MCB-1818283) and the National Institutes of Health (F32-GM143897).

    [ad_2]

    University of California, Berkeley

    Source link

  • Tobacco and e-cigs may put healthy young people at risk of severe COVID illness, new UCLA research suggests

    Tobacco and e-cigs may put healthy young people at risk of severe COVID illness, new UCLA research suggests

    [ad_1]

    EMBARGOED FOR USE UNTIL 5 p.m. PT/8 p.m. ET on Thursday, Feb. 9, 2023

    Newswise — New UCLA research suggests that smoking tobacco and vaping electronic cigarettes may increase healthy young people’s risk for developing severe COVID illness.

    This is among the first studies to find that not only smoking tobacco, but also vaping, may predispose people to increased inflammation and future development of severe COVID-19 and the lingering cardiovascular complications that can occur after initial illness from the virus, said Dr. Theodoros Kelesidis, the study’s lead author.

     “The key message is that smoking is the worst, but vaping is not innocent,” said Kelesidis, associate professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA. “This has been shown for many lung diseases but not for COVID. It was a quite interesting and novel finding that vaping changed the levels of key proteins that the virus uses to replicate.”

    The study will be published Feb.9 in the peer-reviewed Journal of Molecular Medicine.

    The investigators examined plasma collected before the pandemic from 45 non-smokers, 30 electronic cigarette vapers, and 29 tobacco cigarette smokers, testing it to measure levels of since-identified proteins that SARS-CoV-2, the virus at the heart of the pandemic, needs in order to replicate. These proteins are ACE2, furin, Ang II, Ang 1–7, IL-6R, sCD163, L-selectin. The three latter proteins are collectively regulated in cells by a protein known as ADAM17.

    They found that plasma from healthy young people who smoke tobacco or vape had increased levels of furin, sCD163, and L-selectin compared to non-smokers. These data suggest that there may be increased activity of the proteins furin and ADAM17 in the immune cells as well as surface cells, such as those lining the lungs, in healthy young smokers and vapers.

    “E-cigarette vapers may be at higher risk than non-smokers of developing infections and inflammatory disorders of the lungs,” Kelesidis said.  “Electronic cigarettes are not harmless and should be used for only the shortest time possible in smoking cessation, and not at all by nonsmokers.”

    Limitations include the small size of the study, which suggests the need for research with a larger sample size; the reliance on testing blood plasma rather than tissue samples such as lung cells that are believed to be affected by smoking and vaping, which also warrants deeper research; and a lack of evidence of the role that the ADAM17 proteins may play in severe COVID illness among non-smokers.

    Study co-authors are Madhav Sharma, Sandro Satta, Elizabeth Tran, Rajat Gupta, Dr. Jesus Araujo, and Dr. Holly Middlekauff of UCLA.

    The study was funded by the National Institutes of Health (NIH), the Tobacco-Related Disease Research Program (TRDRP 28IR0065), the University of California Office of the President (R00RG2749 Emergency COVID-19 Research Seed Funding), and by the NIH National Center for Advancing Translational Science (NCATS) UCLA CTSI (L1TR001881).

     

    [ad_2]

    University of California, Los Angeles (UCLA), Health Sciences

    Source link

  • Mosquito’s DNA could provide clues on gene expression, regulation

    Mosquito’s DNA could provide clues on gene expression, regulation

    [ad_1]

    Newswise — HOUSTON – (Feb. 9, 2023) – When it comes to DNA, one pesky mosquito turns out to be a rebel among species.

    Researchers at Rice University’s Center for Theoretical Biological Physics (CTBP) are among the pioneers of a new approach to studying DNA. Instead of focusing on chromosomes as linear sequences of genetic code, they’re looking for clues on how their folded 3D shapes might determine gene expression and regulation.

    For most living things, their threadlike chromosomes fold to fit inside the nuclei of cells in one of two ways. But the chromosomes of the Aedes aegypti mosquito — which is responsible for the transmission of tropical diseases such as denguechikungunyazikamayaro and yellow fever — defy this dichotomy, taking researchers at the CTBP by surprise.

    The Aedes aegypti’s chromosomes organize as fluid-yet-oriented “liquid crystals,” different from all other species, according to their study published in Nature Communications.

    “Understanding DNA is a key to understanding how life works,” said Rice theoretical physicist Peter Wolynes, a co-author on the study. “We are only just beginning to learn how the 3D architecture of chromosomes influences the functioning of genomes.”

    A 2021 collaborative study co-led by a team from the CTBP and published in Science reported that chromosomes display one of two structural patterns when cells are not dividing, the stage in the cell life cycle known as interphase.

    “In a ‘type two’ genome architecture — like that found in humans and chickens, for instance — chromosomes form territories and don’t mix together that much,” said Vinícius Contessoto, a CTBP research scientist who is a lead co-author on the latest study and was also a co-author on the 2021 study.

    The still-unknown forces that keep active and inactive parts of “type two” chromosomes separate from each other during interphase behave like those that prevent oil and water from mixing together.

    “In a ‘type one’ architecture, like that found in yeast or in many plants, the regions of the chromosomes known as centromeres come together, folding them into an intermeshed, hairpin-like structure, polarized with telomeres ” said José Onuchic, Rice’s Harry C. and Olga K. Wiess Professor of Physics and Astronomy, and a professor of chemistry and biosciences.

    “Something that’s surprising to me is that even though so many different species have been mapped, they still largely fall into one of these two different classes,” Wolynes said. “The Aedes aegypti mosquito is the first real outlier.”

    The genome of the Aedes aegypti is roughly half the length of the human genome and is organized into six large chromosomes, as opposed to humans’ 46. “We used to think that the chromosomes of the mosquito did not form territories, but in fact they do form these elongated territories,” Contessoto said.

    “During interphase, ‘type two’ chromosomes are really very fluid, disordered things balled up into droplet-shaped territories,” said Wolynes, Rice’s Bullard-Welch Foundation Professor of Science and a professor of chemistry, of biochemistry and cell biology, of physics and astronomy, and of materials science and nanoengineering and co-director of the CTBP.

    The chromosomes of the Aedes aegypti mosquito display fluid characteristics, separating from one another like liquid droplets of oil and water. At the same time, they are partially condensed by compaction forces, which gives them an unusual shape, oriented like an overlong football, suggesting their consistency is also similar to that of a crystal.

    Moreover, if force is applied to a regular “type two” nucleus and it is deformed, the organization of the chromosomes inside remains unaffected. “It’s like poking a water balloon — it reverts to its prior shape. But when we poke the nucleus of the mosquito cells, the chromosomes’ patterns inside change dramatically,” said Onuchic.

    “This is an intriguing feature of ‘type one’ chromosome architecture that suggests there is a possible mechanism linking gene regulation to mechanical inputs on the cell,” said Onuchic. In 2020, he and collaborators confirmed the existence of a mechanism connecting genome structure to gene expression.

    Other co-authors of the new study are Erez Lieberman Aiden, a Rice adjunct assistant professor of computer science and an assistant professor of computational and applied mathematics, an associate professor of molecular and human genetics and a principal investigator in the joint Rice/Baylor College of Medicine Center for Genome Architecture; Olga Dudchenko, an assistant professor in the Center for Genome Architecture and former CTBP postdoctoral fellow; and Michele Di Pierro, an assistant professor of physics at Northeastern University. All are CTBP members.

    The research was supported by the National Science Foundation (2019745, 2210291, 2019276, 2021795); the Welch Foundation (C-1792, Q-1866); the Cancer Prevention and Research Institute of Texas; the São Paulo State Research Foundation and Higher Education Personnel, and Higher Education Personnel Improvement Coordination (2016/13998-8, 2017/09662-7); the D.R. Bullard-Welch Chair at Rice (C-0016); the McNair Medical Institute Scholar Award; the National Institutes of Health (UM1HG009375, RM1HG011016-01A1, R35GM146852); and the AMD HPC Fund.

    -30-

    This release can be found online at news.rice.edu.

    Follow Rice News and Media Relations via Twitter @RiceUNews.

    Peer-reviewed paper:

    Interphase chromosomes of the Aedes aegypti mosquito are liquid crystalline and can sense mechanical cues | Nature Communications | DOI: 10.1038/s41467-023-35909-2

    https://doi.org/10.1038/s41467-023-35909-2

    Authors: Vinícius Contessoto, Olga Dudchenko, Erez Lieberman Aiden, Peter Wolynes, José Onuchic and Michele Di Pierro

    Image downloads:

    https://news-network.rice.edu/news/files/2023/02/CTBP_NatureCommunications_image1_LG.jpg

    CAPTION: 3D simulation of the genome structure of the Aedes aegypti mosquito. The elongated territories formed by each of the six chromosomes are color-coded and shown separately (bottom) and together as part of the whole genome (top). (Image adapted from Nature Communications, https://doi.org/10.1038/s41467-023-35909-2, under a Creative Commons Attribution 4.0 International License.)

    https://news-network.rice.edu/news/files/2023/02/CTBP_NatureCommunications_image2_LG.jpg
    CAPTION: The image shows the effects of applying tension to cell nuclei on contacts between the chromosomes of both the human and mosquito genomes (red and white squares), with corresponding 3D simulations (colorful stringlike structures). The human interphase chromosome is less sensitive to mechanical cues than the mosquito interphase chromosome. (Image adapted from Nature Communications, https://doi.org/10.1038/s41467-023-35909-2, under a Creative Commons Attribution 4.0 International License.)

    https://news-network.rice.edu/news/files/2023/02/230203_Vinicius-Contessoto_LG.jpg
    CAPTION: Vinícius Contessoto is a researcher in the Center for Biological Theoretical Physics at Rice University. (Photo by Gustavo Raskosky/Rice University)

    https://news-network.rice.edu/news/files/2023/02/230203_Onuchic_LG.jpg
    CAPTION: José Onuchic is the Harry C. and Olga K. Wiess Chair of Physics and professor of chemistry and biosciences at Rice University. (Photo by Gustavo Raskosky/Rice University)

    https://news-network.rice.edu/news/files/2023/02/230203_ContessotoOnuchic_LG.jpg
    CAPTION: Vinícius Contessoto (left) and José Onuchic are lead co-authors on the study published last month in Nature Communications. (Photo by Gustavo Raskosky/Rice University)

    Related stories:

    NSF extends Physics of Living Systems network at Rice:
    https://news2.rice.edu/2021/09/27/nsf-extends-physics-of-living-systems-network-at-rice/

    Biologists construct a ‘periodic table’ for cell nuclei:
    https://news.rice.edu/news/2021/biologists-construct-periodic-table-cell-nuclei

    At our cores, we’re all strengthened by ‘dumbbells’:
    https://news.rice.edu/news/2020/our-cores-were-all-strengthened-dumbbells

    Snake-like proteins can wrangle DNA:
    https://news.rice.edu/news/2020/snake-proteins-can-wrangle-dna

    Ring-shaped protein complex wrangles DNA:
    https://news2.rice.edu/2018/11/02/ring-shaped-protein-complex-wrangles-dna/

    Links:

    BioScience Research Collaborative: https://brc.rice.edu/

    Center for Theoretical Biological Physics: https://ctbp.rice.edu/

    Department of Chemical and Biomolecular Engineering: https://chbe.rice.edu/

    Department of Chemistry: https://chemistry.rice.edu/

    Department of Physics and Astronomy: https://physics.rice.edu/

    George R. Brown School of Engineering: https://engineering.rice.edu

    Ken Kennedy Institute: https://kenkennedy.rice.edu/

    Wiess School of Natural Sciences: https://naturalsciences.rice.edu

    Wolynes Research Lab: https://wolynes.rice.edu/

    Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 4,552 undergraduates and 3,998 graduate students, Rice’s undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 1 for quality of life by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance.

    [ad_2]

    Rice University

    Source link

  • Microbiome disturbances reported as signature of chronic fatigue syndrome/myalgic encephalomyelitis

    Microbiome disturbances reported as signature of chronic fatigue syndrome/myalgic encephalomyelitis

    [ad_1]

    Newswise — New research reveals differences in the gut microbiomes of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) compared to those of healthy controls.

    ME/CFS is characterized by unexplained debilitating fatigue, cognitive dysfunction, gastrointestinal disturbances, among other symptoms.

    The study was led by scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health, as part of the Center for Solutions for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, an inter-disciplinary, inter-institutional research group dedicated to understanding the biology of the disease in order to develop effective means to diagnose, treat and prevent it. Findings appear in the journal Cell Host & Microbe.

    The researchers conducted metagenomic and metabolomic analyses of fecal samples collected from geographically diverse cohort of 106 cases and 91 healthy controls. Results revealed differences in gut microbiome diversity, abundances, functional biological pathways, and interactions between bacteria. Cases and controls were matched for age, sex, geography, and socioeconomic status.

    Gut bacteria Faecalibacterium prausnitzii and Eubacterium rectale, which are both normally abundant and health-promoting, were reduced in ME/CFS participants. For both bacteria, researchers also found a deficient microbial capacity for synthesizing butyrate, the main fuel for the body’s colon cell, with ME/CFS. The abundance of Faecalibacterium prausnitzii was inversely associated with fatigue severity.

    The only other species identified with reduced relative abundance in ME/CFS was C. secundus, an acetate-producer, that could contribute to the net acetate deficiency the researchers found in ME/CFS subjects. Acetate is used by butyrate-producing bacteria to produce butyrate.

    An additional nine species had increased relative abundance in ME/CFS compared to healthy controls, including C. bolteae which in other research has correlated with fatigue in multiple sclerosis. Another, R. gnavus, has been associated with inflammatory bowel disease.

    “The gut microbiome is a complex ecological community teeming with diverse inter-species interactions that can be beneficial or harmful. Our research finds that in people with ME/CFS, there can be extensive rewiring of the networks of bacteria in this system,” says study senior author Brent Williams, PhD, assistant professor of epidemiology in CII at Columbia Mailman School of Public Health.

    “Understanding the connection between ME/CFS and disturbances in the gut microbiome may lead to ways to classify the disease and targets for therapeutic trials,” adds co-author W. Ian Lipkin, MD, CII director and John Snow Professor of Epidemiology at Columbia Mailman School.

    The study’s first author is Cheng Guo, PhD, senior programmer analyst at CII. Additional co-authors are listed in the publication.

    The research was funded by the National Institutes of Health grant to the Center for Solutions for ME/CFS at Columbia University (grant number 1U54AI138370), NIH grant R56AI120724, and anonymous donors through the Crowdfunding Microbe Discovery Project.

    The authors declare no competing interests.

    About ME/CFS

    Experts estimate there are between 800,000 and 2 million Americans with ME/CFS, a complex, debilitating disorder characterized by extreme fatigue after exertion and other symptoms including muscle and joint pain, cognitive dysfunction, sleep disturbance, and orthostatic intolerance. Currently, there is no diagnostic test for the disease; instead, patients are diagnosed based on a clinical examination and history and an exclusion of other disorders.

    Prior Research on ME/CFS

    In a 2017 study, CII scientists reported discovered abnormal levels of specific gut bacteria related to ME/CFS in patients with and without concurrent irritable bowel syndrome, IBS. A year later, another study identified a constellation of metabolites related to ME/CFS, providing the ability to predict whether or not someone has the disorder with a confidence of 84 percent.

    In a 2015 study, CII researchers identified distinct immune changes in patients diagnosed with ME/CFS. These immune signatures represented the first robust physical evidence that ME/CFS is a biological illness as opposed to a psychological disorder, and the first evidence that the disease has distinct stages. In a 2012 study, researchers ruled out a purported link between a mouse retrovirus called XMRV and ME/CFS.

    [ad_2]

    Columbia University, Mailman School of Public Health

    Source link

  • $3 million national grant to fund pancreatic cancer study

    $3 million national grant to fund pancreatic cancer study

    [ad_1]

    Newswise — UC Davis Comprehensive Cancer Center is partnering with TargaGenix and Northeastern University to study pancreatic ductal adenocarcinoma (PDAC). The often-lethal cancer has an average five-year survival rate of less than 11%. The academic-industry partnership will receive nearly $3 million over five years thanks to National Institutes of Health (NIH) funding through its R01 grant program. The NIH gives R01 grants only to mature research projects driven by strong preliminary data.

    The team will develop a treatment based on the novel chemotherapy TGX-1214, in combination with cancer immunotherapy. The researchers expect that by the end of the study, this will become part of a new treatment option for PDAC patients.

    PDAC accounts for more than 90% of pancreatic cancer cases. It is usually diagnosed at a late stage when disease has spread to other organs. Symptoms are often common and non-specific, such as lack of appetite and weight loss. By the time symptoms appear, the disease is at a late stage, making it inoperable and incurable.

    Current challenges treating pancreatic cancer

    “Surgery, which offers the only realistic hope for a cure, is a viable option in only a limited number of patients, and current chemotherapy and radiation therapy offer limited or no benefit at all,” UC Davis pancreatic cancer researcher Gerardo Mackenzie said.

    Mackenzie is an associate professor in the Department of Nutrition. He and UC Davis oncologist and Medical Director of the cancer center’s Office of Clinical Research Edward J. Kim are the UC Davis principal investigators for the study.

    “The current chemotherapy combinations used to treat PDAC have marginally improved survival outcomes. The average survival in advanced disease is still less than a year. The limited benefit of these therapies, unfortunately, comes at the cost of significant toxicities, including suppressed immune system, fatigue, nausea, diarrhea, and nerve damage, limiting their use to patients with relatively preserved function,” Kim said, “And most patients still ultimately relapse and progress.”

    In addition, studies show that new immuno-oncology agents, such as anti-PD-1 or anti-CTLA-4 are not effective in PDAC. This is partly because the drugs create a microenvironment that weakens the immune system and prevent cancer-fighting T-cells from entering the tumor mass.

    “That’s why there is a critical unmet need to develop better therapeutic options for aggressive and refractory PDAC,” said distinguished professor of pharmaceutical sciences and chemical engineering at Northeastern University. Amiji is Northeastern’s principal investigator for the study and the scientific advisor for TargaGenix. “We are pleased to collaborate with colleagues at UC Davis and TargaGenix on this research. Based on the high mortality associated with pancreatic cancer, the opportunity for us to develop TGX-1214 for this dreadful disease is especially exciting.”

    Promising TGX-1214 combination strategy for the treatment of advanced pancreatic cancer

    The team will leverage the multi-disciplinary expertise of scientists and clinicians to develop an effective treatment based on the combination of TGX-1214 and immune checkpoint inhibition, which block proteins called checkpoints. Immune checkpoint inhibitors help T cells kill cancer cells better.

    Previous studies indicate that TGX-1214 is safe and effective in multiple animal studies. In preliminary studies, TGX-1214 strongly inhibited pancreatic cancer growth, with complete tumor regression in two pre-clinical models of pancreatic cancer.

    The long-term goal of the research is to develop safe and effective treatment strategies for PDAC to test in clinical trials that will become available for patients.

    [ad_2]

    UC Davis Comprehensive Cancer Center

    Source link

  • When bugs swipe left

    When bugs swipe left

    [ad_1]

    Newswise — It’s almost Valentine’s Day, and love is in the air. Or in the waxy coating on your skin, if you are a vinegar fly. That’s where flies encounter pheromones that play an important role in regulating sexual attraction.

    Flies use pheromones to ensure that they court and mate with members of the same species. As new fly species split off from a common ancestor, but continue to share the same environment, they need a way to rapidly diversify their pheromones to suppress inter-species mating. When members of two related species stop finding each other attractive, this helps prevent interbreeding.

    But it’s more complicated than “she loves me, she loves me not.

    Because the perception and production of pheromones are mediated by different tissues and cellular pathways, evolving new mating pheromones requires a coordinated evolution of both the genes responsible for sensing the pheromones as well as the genes that produce them.

    A new study in iScience led by Yehuda Ben-Shahar at Washington University in St. Louis identifies a link between the genetic instructions for the production and perception of sex pheromones. The research was conducted in collaboration with Jocelyn Millar from the University of California, Riverside.

    Researchers reported that a single protein called Gr8a is expressed in different organs in male and female flies and appears to play an inhibitory role in mating decision-making. The findings point to one of the ways that flies could put up behavioral barriers to protect against mating with the wrong kind of partner.

    “Mating pheromones often show rapid evolution,” said Ben-Shahar, a professor of biology in Arts & Sciences. “Because pheromonal communication requires a very robust and specific structural recognition of chemicals used as pheromones by the proteins that bind them in sensory neurons (chemoreceptors), it means that major molecular changes in either the receptor or the pheromone would reduce sexual attraction between males and females.”

    Ben-Shahar and his team found that Gr8a was expressed in tissues in fly mouthparts, including the proboscis, as well as in taste neurons in the forelegs of both males and females. They also found Gr8a in cells in the abdomens of males. This was important because it provided Ben-Shahar and his team the first hint that a gene that had been previously identified as a sensory chemoreceptor must also have non-neuronal functions.

    “Our findings provide a relatively simple molecular explanation for how signal production and perception are tied together in vinegar flies,” Ben-Shahar said. “A single pleiotropic protein can function as both a receptor for pheromones in sensory neurons, as well as contribute to their production in the pheromone-producing cells (oenocytes) of males, by way of a less-understood process.”

    In one of the experiments that Ben-Shahar and his team conducted, the scientists took flies that were mutant for the Gr8a receptor and reconstituted them using input from a different vinegar fly species. This experiment showed that introducing Gr8a from another species was enough to change the overall pheromone profile of the animal.

    The scientists still have not pinpointed exactly how the chemoreceptor affects the way the signal is produced, but they do know that it causes quantitative and qualitative differences in pheromones. And even small changes in pheromones could be enough to keep closely related flies from finding each other attractive — and change their mate choice behaviors.

    The question of how closely related species evolve and maintain behavioral mating barriers is one that has implications for several different basic and applied biological research fields.

    “Based on what we have observed, mutations in a single gene could provide a molecular path for a pheromonal communication system to evolve while still maintaining the functional coupling between a pheromone and its receptor,” Ben-Shahar said. “Our research uncovers a potential avenue for pheromonal systems to rapidly evolve when new species arise.”

    This work was supported by National Science Foundation grants 1322783, 1754264 and 1707221, and National Institutes of Health (NIH) grant NS089834.

    [ad_2]

    Washington University in St. Louis

    Source link

  • Study Links Key Activating Enzymes to Specific Sites on Proteins in Cells

    Study Links Key Activating Enzymes to Specific Sites on Proteins in Cells

    [ad_1]

    RESEARCH SUMMARY

    Study Title: An atlas of substrate specificities for the human serine/threonine kinome

    Publication: Nature (Online) January 11, 2023   https://www.nature.com/articles/s41586-022-05575-3

    Dana-Farber Cancer Institute author: Lewis C. Cantley, PhD

    Summary:

    Thousands of proteins in a human cell are regulated by phosphorylation — the addition of small chemical groups to the proteins’ amino acids by enzymes called protein kinases. This process is known as phosphorylation. Abnormal protein phosphorylation has been implicated in a number of diseases, notably cancer and degenerative diseases like Parkinson’s and Alzheimer’s. Some 90,000 sites of phosphorylation on serine and threonine amino acids have been identified, but it hasn’t been known which of more than 300 protein serine or threonine kinases are responsible. In a new study, researchers at Weill Cornell Medicine and Dana-Farber Cancer Institute purified and characterized the substrate specificity of essentially all the human protein-serine/threonine kinases and developed a computational method to identify the kinases capable of phosphorylating every known phosphorylation site in the human serine/threonine proteome.

    Impact:

    Several thousand sites of serine and threonine phosphorylation have been associated with human diseases, including cancers and diabetes. The new study provides a mechanism for rapidly identifying the protein kinase that is driving the abnormal behavior of individual cancers.  Since many drugs for inhibiting protein kinases are already approved or in clinical trials, this information can rapidly lead to a new therapy that can be individualized to the patient.

    Funding:

    The research was supported by the Leukemia & Lymphoma Society and grants from the National Institutes of Health; the Cancer Research UK and Brain Tumor Charity; the Charles and Marjorie Holloway Foundation, and the MIT Center for Precision Cancer Medicine.

     

     

    [ad_2]

    Dana-Farber Cancer Institute

    Source link

  • Overdose deaths involving buprenorphine did not proportionally increase with new flexibilities in prescribing

    Overdose deaths involving buprenorphine did not proportionally increase with new flexibilities in prescribing

    [ad_1]

    Newswise — The proportion of opioid overdose deaths involving buprenorphine, a medication used to treat opioid use disorder, did not increase in the months after prescribing flexibilities were put in place during the COVID-19 pandemic, according to a new study. These data provide evidence that may help to inform buprenorphine prescribing policies. Published today in JAMA Network Openthis study was a collaborative effort between researchers at the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, and the Centers for Disease Control and Prevention (CDC).

    These data are consistent with a recent study reporting that COVID-era expansion of methadone access for the treatment of opioid use disorder was not associated with an increase in methadone-involved overdose deaths.

    In 2021, nearly 107,000 people died of a drug overdose, with 75% of those deaths involving an opioid. The overall rise in overdose deaths is largely attributable to the proliferation in the drug supply of illicit fentanyl, a highly potent synthetic opioid. Though the benefits of providing medication for opioid use disorder are well-known, only 22% of people with opioid use disorder receive medications. Buprenorphine, one of these medications, helps reduce opioid misuse, decrease risk for injection-related infectious diseases, and decrease risk for fatal and non-fatal overdoses.

    “Research has shown beyond a doubt that medications for opioid use disorder are overwhelmingly beneficial and can be lifesaving, yet they continue to be vastly underused,” said NIDA Director and senior author, Nora Volkow, M.D. “Expanding more equitable access to these medications for people with substance use disorders is a critical part of our nation’s response to the overdose crisis. The findings from this study strengthen existing evidence suggesting that greater flexibility in prescribing may be one safe method for working toward this goal.”

    While the recently signed Fiscal Year 2023 omnibus appropriations bill amended the Controlled Substances Act to eliminate the requirement that clinicians obtain a specific waiver to prescribe buprenorphine to treat opioid use disorder, buprenorphine remains a Schedule III controlled substance with restrictions on prescribing. During the onset of the COVID-19 pandemic, the United States government implemented prescribing flexibilities to facilitate buprenorphine access for patients with opioid use disorder. These updated policies allowed clinicians to remotely prescribe buprenorphine to new patients without conducting in-person examinations, expanded payment for telehealth services, and provided flexibility on accepted communication technologies to deliver clinical care for people with substance use disorders via telehealth. 

    To investigate the impact of these policy changes, researchers used data from the CDC’s State Unintentional Drug Overdose Reporting System (SUDORS) to assess overdose deaths from July 2019 to June 2021 in 46 states and the District of Columbia. SUDORS combines data from death certificates, medical examiner and coroner reports, and postmortem toxicology testing.

    Researchers found that buprenorphine was involved in a very small proportion of drug overdose deaths between July 2019 and June 2021. During this study period, there were 1,955 buprenorphine-involved overdose deaths, which represented 2.2% of the 89,111 total overdose deaths and 2.6% of the 74,474 opioid-involved overdose deaths recorded in the SUDORS dataset. Between April 2020 and June 2021, when buprenorphine prescribing regulations were relaxed in response to the COVID-19 pandemic, the researchers found that while monthly opioid-involved overdose deaths increased overall, the proportion of those deaths involving buprenorphine did not increase.

    Additionally, the study found that 92.7% of buprenorphine-involved overdose deaths also involved at least one other drug, compared to 67.2% of deaths involving an opioid other than buprenorphine. Specifically, compared with other opioid-involved overdose deaths, buprenorphine-involved overdose deaths were more likely to also involve prescription medications such as benzodiazepines (36.9% vs. 14.5%), antidepressants (13.9% vs. 5.0%), and anticonvulsants (18.6% vs. 5.4%). Buprenorphine-involved overdose deaths were less likely to also involve illicitly manufactured fentanyls (50.2%) compared to other opioid-involved overdose deaths (85.3%).

    “These findings help us better understand the circumstances of overdose deaths involving buprenorphine, which is crucial in our ability to inform policy, ensure safety, and improve clinical outcomes for people with substance use disorders,” said Lauren Tanz, Sc.D., an epidemiologist at CDC’s National Center for Injury Prevention and Control and lead author on the study. “It is important to note the presence of other drugs in overdose deaths involving buprenorphine. The complex nature of substance use disorders and polysubstance use requires specific strategies to address it.”

    Data also showed that non-Hispanic white people represented a higher proportion of the deaths involving buprenorphine (86.1%), compared to deaths related to other opioids (69.4%). In contrast, buprenorphine-involved overdose deaths included fewer Black, non-Hispanic people (5.7%), and Hispanic people (5.5%) compared with other opioid-involved overdose deaths (18.8% and 9.4%, respectively), which the authors note might be related to inequitable access to treatment.

    Regardless of the drugs involved, the investigators found that most people who died of an overdose involving any opioid, including buprenorphine, had no evidence of current treatment for substance use disorders. In addition, most deaths occurred without another person being present, a known risk factor for fatal overdose.

    For more information on substance and mental health treatment programs in your area, call the free and confidential National Helpline 1-800-662-HELP (4357) or visit www.FindTreatment.gov. 

    Reference: LJ Tanz, et al. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 PandemicJAMA Network Open. DOI: 10.1001/jamanetworkopen.2022.51856 (2023).

    ###

    About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov.

    About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

    About substance use disorders: Substance use disorders are chronic, treatable conditions from which people can recover. In 2020, over 40 million people in the United States had at least one substance use disorder. Substance use disorders are defined in part by continued use of substances despite negative consequences. They are also relapsing conditions, in which periods of abstinence (not using substances) can be followed by a return to use. Stigma can make individuals with substance use disorders less likely to seek treatment. Using preferred language can help accurately report on substance use and addiction. View NIDA’s online guide.

    NIH…Turning Discovery Into Health®

    [ad_2]

    NIH National Institute on Drug Abuse (NIDA)

    Source link

  • CHOP Researchers Develop New, More Accurate Computational Tool for Long-Read RNA Sequencing

    CHOP Researchers Develop New, More Accurate Computational Tool for Long-Read RNA Sequencing

    [ad_1]

    Newswise — Philadelphia, January 20, 2023—On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein. This process, known as alternative splicing, allows a single gene to encode several different proteins. Alternative splicing occurs in many biological processes, like when stem cells mature into tissue-specific cells. In the context of disease, however, alternative splicing can be dysregulated. Therefore, it is important to examine the transcriptome – that is, all the RNA molecules that might stem from genes – to understand the root cause of a condition.

    However, historically it has been difficult to “read” RNA molecules in their entirety because they are usually thousands of bases long. Instead, researchers have relied on so-called short-read RNA sequencing, which breaks RNA molecules and sequence them in much shorter pieces – somewhere between 200 to 600 bases, depending on the platform and protocol. Computer programs are then used to reconstruct the full sequences of RNA molecules. Short-read RNA sequencing can give highly accurate sequencing data, with a low per-base error rate of approximately 0.1% (meaning one base is incorrectly determined for every 1,000 bases sequenced). Nevertheless, it is limited in the information that it can provide due to the short length of the sequencing reads. In many ways, short-read RNA sequencing is like breaking a large picture into many jigsaw pieces that are all the same shape and size and then trying to piece the picture back together.

    Recently, “long-read” platforms that can sequence RNA molecules over 10,000 bases in length end-to-end have become available. These platforms do not require RNA molecules to be broken up before they are sequenced, but they have a much higher per-base error rate, typically between 5% to 20%. This well-known limitation has severely hampered the widespread adoption of long-read RNA sequencing. In particular, the high error rate has made it difficult to determine the validity of novel, previously unknown RNA molecules discovered in a particular condition or disease.

    To circumvent this problem, researchers at Children’s Hospital of Philadelphia (CHOP) have developed a new computational tool that can more accurately discover and quantify RNA molecules from these error-prone long-read RNA sequencing data. The tool, called ESPRESSO (Error Statistics PRomoted Evaluator of Splice Site Options), was reported today in Science Advances.

    “Long-read RNA sequencing is a powerful technology that will allow us to uncover RNA variation in rare genetic diseases and other conditions, like cancer,” said Yi Xing, PhD, director of the Center for Computational and Genomic Medicine at CHOP and senior author of the study. “We are probably at an inflection point in how we discover and analyze RNA molecules. The transition from short-read to long-read RNA sequencing represents an exciting technological transformation, and computational tools that reliably interpret long-read RNA sequencing data are urgently needed.”

    ESPRESSO can accurately discover and quantify different RNA molecules from the same gene – known as RNA isoforms – using error-prone long-read RNA sequencing data alone. To do so, the computational tool compares all long RNA sequencing reads of a given gene to its corresponding genomic DNA, and then uses the error patterns of individual long reads to confidently identify splice junctions – places where the nascent RNA molecule has been cut and joined – as well as their corresponding full-length RNA isoforms. By finding areas of perfect matches between long RNA sequencing reads and genomic DNA, as well as borrowing information across all long RNA sequencing reads of a gene, the tool is able to identify highly reliable splice junctions and RNA isoforms, including those that have not been previously documented in existing databases. 

    The researchers evaluated the performance of ESPRESSO using simulated data and data on real biological samples. They found that ESPRESSO performs better than multiple currently available tools, both in terms of discovering RNA isoforms and quantifying them. The researchers also generated and analyzed over 1 billion long RNA sequencing reads covering 30 human tissue types and three human cell lines, providing a useful resource for studying human transcriptome variation at the resolution of full-length RNA isoforms. 

    “ESPRESSO addresses a long-standing problem of long-read RNA sequencing and could usher in new opportunities of discovery,” Dr. Xing said. “We envision that ESPRESSO will be a useful tool for researchers to explore the RNA repertoire of cells in various biomedical and clinical settings.”

    This work was supported in part by the Immuno-Oncology Translational Network (IOTN) of the National Cancer Institute’s Cancer Moonshot Initiative (U01CA233074), other National Institutes of Health funding (R01GM088342, R01GM121827, and R56HG012310), along with a National Institutes of Health T32 Training Grant in Computational Genomics (T32HG000046). 

    Gao et al. “ESPRESSO: Robust discovery and quantification of transcript isoforms from error-prone long-read RNA-seq data,” Science Advances, January 20, 2023, DOI: 10.1126/sciadv.abq5072

    #

    About Children’s Hospital of Philadelphia: A non-profit, charitable organization, Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the 595-bed hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as a new inpatient hospital with a dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children’s Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

     

    [ad_2]

    Children’s Hospital of Philadelphia

    Source link

  • Commonly used antiretroviral drugs used to treat HIV and hepatitis B reduce immune cells’ energy production

    Commonly used antiretroviral drugs used to treat HIV and hepatitis B reduce immune cells’ energy production

    [ad_1]

    FINDINGS

    New UCLA-led research suggests that antiretroviral drugs called TAF and TDF directly reduce energy production by mitochondria, structures inside cells that generate the power that cells use to function. Both drugs led to reduced cellular oxygen consumption rates, a measure of the ability of the mitochondria to produce energy, compared with controls. But in combination with other antiretrovirals, TAF appeared to result in a larger energy reduction than TDF did. Whether this is a cause for concern is not known at this point.

    BACKGROUND                                                                                         

    The antiretroviral drugs tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are used to treat HIV and hepatitis B infection in millions of people around the world. These drugs are also used as pre-exposure prophylaxis (PrEP) against HIV in uninfected people.

    METHOD

    Using both a human clinical trial and experimental lab studies, the researchers assessed the impact of TAF and TDF in combination with other antiretrovirals on the ability of blood immune cells to make energy. In the clinical trial, 26 people with HIV switched antiretrovirals over nine months and the researchers assessed how the drugs affected their cells’ energy production. The investigators confirmed these findings experimentally in the lab by directly adding the drugs to healthy immune cells and analyzing their impact on the cells’ metabolism.

    IMPACT

    The clinical implications of the findings are unclear at this point, a question that requires more research. These drugs are well tolerated by millions of people worldwide, but the long-term clinical implications of these drugs on the ability of human cells to make energy is unclear.

    COMMENT

    “Mitochondria are key structures inside the cells. This is the among the first demonstrations that antiretrovirals used in humans in HIV and hepatitis B directly change the function of mitochondria to make energy,” said senior author Dr. Theodoros Kelesidis, associate professor-in-residence of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA. “We utilized independent research methods to confirm our findings. This is an important message, given that millions of people are on these antiretrovirals. It remains to be shown whether the effects of these antiretrovirals on mitochondria are mechanistically linked to certain metabolic changes that may be seen with the use of these antiretrovirals such as weight gain.”

    AUTHORS

    Study co-authors are Eleni Ritou, Sandro Satta, Anton Petcherski, Maria Daskou, Madhav Sharma, Hariclea Vasilopoulos, and Dr. Orian Shirihai of UCLA, and Eisuke Murakami of Gilead Sciences.

    JOURNAL

    The study is published in the peer-reviewed journal Metabolism.

    FUNDING

    The study was supported by Gilead Sciences, Inc. (CO-US-311-4393) and the National Institutes of Health (R01AG059501).

    [ad_2]

    University of California, Los Angeles (UCLA), Health Sciences

    Source link

  • COVID is changing how we are exposed to household health risks

    COVID is changing how we are exposed to household health risks

    [ad_1]

    Newswise — COVID-19 is changing household behaviors related to how we are exposed to various household chemicals linked to poor health outcomes. People surveyed earlier in the pandemic were using less personal care products but more household cleaners, eating less fast food and restaurant food but more ultra-processed food. These changes which occurred since the pandemic onset are also linked to pandemic-related traumatic stress, which itself may worsen health outcomes.

    Researchers at Columbia University Mailman School of Public Health along with partners from Dartmouth College, as part of the Environmental influences on Child Health Outcomes (ECHO) consortium, analyzed responses to a survey from 1,535 adults in six states. Results are published in the journal PLOS ONE.

    Personal care products. Overall, participants reported using fewer personal care products, including hair products (perms or relaxers, hair dye, hair sprays, hair gels) and makeup/body products (nail polish, make-up, perfume, lotion) since the start of the pandemic. Participants who experienced more pandemic-related traumatic stress were more likely to report using fewer hair products and cosmetics. Approximately half of all respondents reported using more liquid soaps (52%) and antibacterial soaps (48%) and 81 percent of respondents reported using more hand sanitizer gels. The use of all three products was associated with pandemic-related traumatic stress symptoms.

    Household cleansers. Two-thirds of respondents reported using more antibacterial cleaners and 54 percent reported using more bleach-containing cleaning products—changes made more likely among those experiencing more pandemic-related traumatic stress.

    Food-related behaviors. Nearly half (49%) of respondents said they eat more home-cooked meals because of the pandemic. One-third (34%) of respondents reported eating less fast food since the start of the pandemic. Both of these behavior changes were more common among those with more symptoms of pandemic-related traumatic stress. In all, 12 percent reported eating more ultra-processed foods, and 24 percent reported eating less processed foods, with the latter more likely among those with symptoms of pandemic-related traumatic stress.

    The Upshot

    While the study did not include measurements of environmental exposures, the researchers say that the scientific literature suggests that these behavior changes likely reflect changes in their exposures to environmental chemicals. They also likely reflect changes—both good and bad—to health outcomes linked to these chemicals.

    “We can infer that some behaviors like less consumption of fast foods and less use of personal care products might lower exposures to some phthalates and phenols, while greater use of personal and household cleansers may be associated with higher exposure to quaternary ammonium compounds and glycol ethers; and more frequent consumption of ultra-processed food could increase exposure to phthalates and phenols,” says lead author Julie Herbstman, PhD, director of the Columbia Center for Children’s Environmental Health (CCCEH) and professor of environmental health sciences.

    Phthalates are linked asthma, attention-deficit hyperactivity disorder, breast cancer, obesity and type II diabetes and neurodevelopmental and behavioral issues. Phenols like BPA are linked to reproductive dysfunction, reduced birth size, cognitive and/or behavior outcomes, asthma, and obesity. Quaternary ammonium compounds are skin irritants and can also lead to asthma exacerbations. Exposure to glycol ethers may also irritate skin, eyes, nose, and throat and may also lead to anemia and/or adverse reproductive outcomes like birth defects.  

    A Roadmap to Interventions

    The study identifies several factors that make some of these behavior changes more likely, including symptoms of pandemic-related traumatic stress and living in a household where someone tested positive for COVID-19, as well as race/ethnicity. Going forward, the researchers plan to repeat their analysis, adding a biological measure of chemical exposures to assess whether the trends in pandemic-related behavior change reported here do, in fact, result in shifts in exposures measured through biomarkers of internal dose. They also say it is important to continue to monitor pandemic-related behavior change as pandemic severity waxes and wanes.

    The researchers say their study could lead to an intervention to reduce exposure to harmful environmental chemicals.

    “Interventions and campaigns targeting the reduction of environmental exposures, pandemic-related traumatic stress, as well as those that facilitate behavior change can help improve health outcomes that are indirectly related to the pandemic,” says Herbstman.

    The study’s senior authors are Frederica Perera, director of the translational research program at CCCEH and professor of environmental health sciences at Columbia Mailman School of Public Health, and Margaret R. Karagas, professor and chair of epidemiology at the Geisel School of Medicine at Dartmouth. A full list of co-authors is available in the journal article.

    Funding for the research was provided by grants from the National Institutes of Heath (U2COD023375, U24OD023382, U24OD023382, U24OD023319, UH3OD023290, UH3OD023275, UH3OD023272, UH3OD023271, UH3OD023313).

    The authors declare no conflicts.

    [ad_2]

    Columbia University, Mailman School of Public Health

    Source link

  • ‘Lights out’ for antibiotic-resistant superbugs

    ‘Lights out’ for antibiotic-resistant superbugs

    [ad_1]

    Newswise — It’s ‘lights out’ for antibiotic-resistant superbugs as next-generation light-activated nanotech proves it can eradicate some of the most notorious and potentially deadly bacteria in the world.

    Developed by the University of South Australia and published in Pharmaceutics, the new light therapy can eliminate antibiotic-resistant superbugs golden staph and pseudomonas aeruginosa by 500,000-fold and 100,000-fold respectively.

    Golden staph (staphylococcus aureus) and pseudomonas aeruginosa are among the most deadly superbugs in the world. Globally, about 1.27 million people die as a result of antibiotic-resistant bacteria.

    Lead researcher, UniSA’s Dr Muhammed Awad, says the new light therapy will be a game-changer for millions of people worldwide.

    Golden staph and pseudomonas aeruginosa are both highly transmissible bacteria, commonly found on people’s skin. But if they get into the blood, they can lead to sepsis or even death,” Dr Awad says.

    “Patients in hospitals – particularly those with wounds or catheters, or those on ventilators – have a higher risk of getting these bacteria, and while antibiotics may help, their extensive use has led to waves of microbial resistance, often making them ineffective.

    “Our photodynamic technology works differently, harnessing the energy of light to generate highly reactive oxygen molecules that eradicate microbial cells and kill deadly bacteria, without harming human cells.”

    The researchers tested the antimicrobial photodynamic therapy on recalcitrant bacterial infections caused by antibiotic resistant strains of golden staph and pseudomonas aeruginosa.

    Senior researcher, UniSA’s Professor Clive Prestidge, says that the technology has some key advantages over conventional antibiotics and other light therapies.

    “The new therapy is created in an oil that that is painted on a wound as a lotion. When laser light is applied to the lotion, it creates reactive oxygen species which act as an alternative to conventional antibiotics,” Prof Prestidge says.

    “Current photoactive compounds also suffer from poor water-solubility which mean that they have limited clinical application.

    “Our approach uses food grade lipids to construct nanocarriers for the photoactive compound which improves its solubility and antibacterial efficiency far beyond that of an unformulated compound.

    “These molecules target multiple bacterial cells at once, preventing bacteria from adapting and becoming resistant. So, it’s a far more effective and robust treatment.

    “Importantly, the human skin cells involved in the wound healing process showed enhanced viability, while the antibiotic resistant bacteria were entirely eradicated.”

    The consequences of not managing superbugs are high. Already, antibiotic resistant microbials cost millions of lives and trillions of dollars to the global economy each year.

    “This technology is very promising and is gaining the attention of scientists worldwide,” Prof Prestidge says.

    “The next step is to commence clinical trials and develop this technology further to be available in clinics. With the support of funding bodies, we hope that Australians will have access to this technology as soon as possible.”

     

    Notes to editors:

    Multiple papers are available upon request: 

    …………………………………………………………………………………………………………………………

    [ad_2]

    University of South Australia

    Source link

  • Evolution of uniquely human DNA was a balancing act, study concludes

    Evolution of uniquely human DNA was a balancing act, study concludes

    [ad_1]

    Newswise — SAN FRANCISCO, CA—January 13, 2023—Humans and chimpanzees differ in only one percent of their DNA. Human accelerated regions (HARs) are parts of the genome with an unexpected amount of these differences. HARs were stable in mammals for millennia but quickly changed in early humans. Scientists have long wondered why these bits of DNA changed so much, and how the variations set humans apart from other primates.

    Now, researchers at Gladstone Institutes have analyzed thousands of human and chimpanzee HARs and discovered that many of the changes that accumulated during human evolution had opposing effects from each other.

    “This helps answer a longstanding question about why HARs evolved so quickly after being frozen for millions of years,” says Katie Pollard, PhD, director of the Gladstone Institute of Data Science and Biotechnology and lead author of the new study published today in Neuron. “An initial variation in a HAR might have turned up its activity too much, and then it needed to be turned down.”

    The findings, she says, have implications for understanding human evolution. In addition—because she and her team discovered that many HARs play roles in brain development—the study suggests that variations in human HARs could predispose people to psychiatric disease.

    “These results required cutting-edge machine learning tools to integrate dozens of novel datasets generated by our team, providing a new lens to examine the evolution of HAR variants,” says Sean Whalen, PhD, first author of the study and senior staff research scientist in Pollard’s lab.

    Enabled by Machine Learning

    Pollard discovered HARs in 2006 when comparing the human and chimpanzee genomes. While these stretches of DNA are nearly identical among all humans, they differ between humans and other mammals. Pollard’s lab went on to show that the vast majority of HARs are not genes, but enhancers— regulatory regions of the genome that control the activity of genes.

    More recently, Pollard’s group wanted to study how human HARs differ from chimpanzee HARs in their enhancer function. In the past, this would have required testing HARs one at a time in mice, using a system that stains tissues when a HAR is active.

    Instead, Whalen input hundreds of known human brain enhancers, and hundreds of other non-enhancer sequences, into a computer program so that it could identify patterns that predicted whether any given stretch of DNA was an enhancer. Then he used the model to predict that a third of HARs control brain development.

    “Basically, the computer was able to learn the signatures of brain enhancers,” says Whalen.

    Knowing that each HAR has multiple differences between humans and chimpanzees, Pollard and her team questioned how individual variants in a HAR impacted its enhancer strength. For instance, if eight nucleotides of DNA differed between a chimpanzee and human HAR, did all eight have the same effect, either making the enhancer stronger or weaker?

    “We’ve wondered for a long time if all the variants in HARs were required for it to function differently in humans, or if some changes were just hitchhiking along for the ride with more important ones,” says Pollard, who is also chief of the division of bioinformatics in the Department of Epidemiology and Biostatistics at UC San Francisco (UCSF), as well as a Chan Zuckerberg Biohub investigator.

    To test this, Whalen applied a second machine learning model, which was originally designed to determine if DNA differences from person to person affect enhancer activity. The computer predicted that 43 percent of HARs contain two or more variants with large opposing effects: some variants in a given HAR made it a stronger enhancer, while other changes made the HAR a weaker enhancer.

    This result surprised the team, who had expected that all changes would push the enhancer in the same direction, or that some “hitchhiker” changes would have no impact on the enhancer at all.

    Measuring HAR Strength

    To validate this compelling prediction, Pollard collaborated with the laboratories of Nadav Ahituv, PhD, and Alex Pollen, PhD, at UCSF. The researchers fused each HAR to a small DNA barcode. Each time a HAR was active, enhancing the expression of a gene, the barcode was transcribed into a piece of RNA. Then, the researchers used RNA sequencing technology to analyze how much of that barcode was present in any cell—indicating how active the HAR had been in that cell.

    “This method is much more quantitative because we have exact barcode counts instead of microscopy images,” says Ahituv. “It’s also much higher throughput; we can look at hundreds of HARs in a single experiment.”

    When the group carried out their lab experiments on over 700 HARs in precursors to human and chimpanzee brain cells, the data mimicked what the machine learning algorithms had predicted.

    “We might not have discovered human HAR variants with opposing effects at all if the machine learning model hadn’t produced these startling predictions,” said Pollard.

    Implications for Understanding Psychiatric Disease

    The idea that HAR variants played tug-of-war over enhancer levels fits in well with a theory that has already been proposed about human evolution: that the advanced cognition in our species is also what has given us psychiatric diseases.

    “What this kind of pattern indicates is something called compensatory evolution,” says Pollard. “A large change was made in an enhancer, but maybe it was too much and led to harmful side effects, so the change was tuned back down over time—that’s why we see opposing effects.”

    If initial changes to HARs led to increased cognition, perhaps subsequent compensatory changes helped tune back down the risk of psychiatric diseases, Pollard speculates. Her data, she adds, can’t directly prove or disprove that idea. But in the future, a better understanding of how HARs contribute to psychiatric disease could not only shed light on evolution, but on new treatments for these diseases.

    “We can never wind the clock back and know exactly what happened in evolution,” says Pollard. “But we can use all these scientific techniques to simulate what might have happened and identify which DNA changes are most likely to explain unique aspects of the human brain, including its propensity for psychiatric disease.”

    ###

    About the Study

    The paper “Machine learning dissection of human accelerated regions in primate neurodevelopment,” was published in the journal Neuron on January 13, 2023.

    Other authors are Kathleen Keough, Alex Williams, Md. Abu Hassan Samee, and Sean Thomas of Gladstone; Fumitaka Inoue, Hane Ryu, Tyler Fair, Eirene Markenscoff-Papadimitrious, Beatriz Alvarado, Orry Elor, Dianne Laboy Cintron, Erik Ullian, Arnold Kriegstein, and John Rubenstein of UC San Francisco; Martin Kircher, Beth Martin, and Jay Shendure of University of Washington; and Robert Krencik of Houston Methodist Research Institute.

    The work was supported by the Schmidt Futures Foundation and the National Institutes of Health (DP2MH122400-01, R35NS097305, FHG011569A, R01MH109907, U01MH116438, UM1HG009408, UM1HG011966, 2R01NS099099).

    About Gladstone Institutes

    To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco.

    [ad_2]

    Gladstone Institutes

    Source link

  • Lab lights way to simple chemical synthesis

    Lab lights way to simple chemical synthesis

    [ad_1]

    Newswise — HOUSTON – (Jan. 6, 2023) – Inexpensive iron salts are a key to simplifying the manufacture of essential precursors for drugs and other chemicals, according to scientists at Rice University.

    They’ve refined the process of producing diazides, building-block molecules in the production of drugs and agricultural chemicals. Iron salts along with processes called radical ligand transfer and ligand-to-metal charge transfer (LMCT) make it affordable and environmentally friendly.

    Rice synthetic chemist Julian West and co-lead authors Kang-Jie (Harry) Bian and Shih-Chieh Kao, both graduate students in his lab, report in Nature Communications that illuminating their reagents with visible light allows them to form diazides in conditions that are far more gentle than current industrial processes that usually involve high heat and corrosive acids.

    Diazides are molecules with two amine groups that can be functionalized, meaning they can easily react with other molecules. Depending on how they’re constructed, they can be the basis of many useful compounds.

    In a recent study, West and his group used radical ligand transfer (or “radical rebound”) to add two functional groups to a single alkene, organic molecules drawn from petrochemicals that contain at least one carbon-carbon double bond.

    The technique, along with iron-mediated ligand-to-metal charge transfer, came in handy as they built similar precursors called vicinal diazides out of common feedstocks.

    “It only uses two reagents, iron nitrate and TMS azide, which every synthetic lab will have,” said West, an assistant professor of chemistry whose lab strives to simplify drug manufacturing. “Basically, you mix them together in a common solvent and shine light on it. Most every pharmaceutical lab will have LED lights. So basically they’ll just pull things off the shelf.”

    West said radical ligand transfer was inspired by biology, “including the enzymes in our own livers. There are enzymes in nature that transfer atoms or fragments of molecules to a radical to make a new bond that can help build up bigger molecules. We were excited to explore the potential of that one step in the last study.

    “In this project, now that we’ve established how that works, we can start to combine it with new steps to make something different,” he said. “The funny thing is, like with everything in organic chemistry, nature appreciated a long time ago that this can be really useful.”

    Both LMCT and radical ligand transfer happen, one after the other, when the reagents and solution are illuminated in ambient conditions. The lab learned to maximize the process through flow chemistry, running the solution through a looping tube and lighting just that tube.

    “The reaction happens in the part where you shine the light,” West said. “That way we can process more than a single batch, and also have much more control over the amount of light it’s getting by speeding up or slowing down the flow.

    “It’s dead easy to dump the salts in the flask and shine a light on it, but if you want to make a lot, or make it better, flow works really well,” he said. 

    “We think it will be helpful for labs that want an easy way to make this kind of product, especially if they don’t have the time to fine tune and fight with getting these other methods to work well,” West said.

    Study co-authors include Rice undergraduates David Nemoto Jr. and Xiaowei Chen.

    The research was supported by Cancer Prevention and Research Institute of Texas (RR190025), the National Institutes of Health (GM142738) and the Welch Foundation (C-2085).

    -30-

    Peer-reviewed paper:

    “Photochemical diazidation of alkenes enabled by ligand-to-metal charge transfer and radical ligand transfer” | Nature Communications | DOI: 10.1038/s41467-022-35560-3

    Kang-Jie Bian, Shih-Chieh Kao, David Nemoto Jr., Xiao-Wei Chen and Julian G. West

    https://www.nature.com/articles/s41467-022-35560-3.pdf

    Images for download:

    https://news-network.rice.edu/news/files/2022/12/1212_DIAMINES-1-web.jpg
    CAPTION: A mild solution containing reagents passes through an illuminated loop in a Rice University laboratory. The lab has developed a photochemical process to simplify the synthesis of drug and chemical precursors known as diamines. (Credit: West Research Lab/Rice University)

    https://news-network.rice.edu/news/files/2022/12/1212_DIAMINES-2-web.jpg
    CAPTION: This illuminated loop rig helps Rice University chemists use flow photochemistry to produce diamines, building-block molecules in the production of drugs and agricultural chemicals. (Credit: West Research Lab/Rice University)

    https://news-network.rice.edu/news/files/2022/12/1212_DIAMINES-3-web.jpg
    CAPTION: The synergistic cooperation of ligand-to-metal charge transfer and radical ligand transfer produces diamines, building-block molecules in the production of drugs and agricultural chemicals. Rice University chemists introduced their light-driven process in Nature Communications. (Credit: West Research Lab/Rice University)

    https://news-network.rice.edu/news/files/2022/12/1212_DIAMINES-4a-web.jpg
    CAPTION: From left, Rice University graduate students Kang-Jie (Harry) Bian and Shih-Chieh Kao and undergraduate student David Nemoto Jr. who, along with undergraduate Xiaowei Chen (inset), developed a light-driven method to synthesize diamines to simplify drug and chemical design. (Credit: Rice University)

    https://news-network.rice.edu/news/files/2022/12/1212_DIAMINES-5-WEB-JULIAN-WEST.jpg
    CAPTION: Julian West is the Norman Hackerman-Welch Young Investigator and an assistant professor in Rice University’s Department of Chemistry. (Credit: Rice University)

    Related stories:

    Process to customize molecules does double duty – June 22, 2022
    https://news.rice.edu/news/2022/process-customize-molecules-does-double-duty

    Manganese makes its mark in drug synthesis – Oct. 5, 2021
    https://news.rice.edu/news/2021/manganese-makes-its-mark-drug-synthesis

    NIH grant will help streamline chemical synthesis – Jul. 5, 2021 https://news.rice.edu/news/2021/nih-grant-will-help-streamline-chemical-synthesis

    Cerium sidelines silver to make drug precursor – Feb. 26, 2021
    https://news.rice.edu/news/2021/cerium-sidelines-silver-make-drug-precursor

    Links:

    West Research Group: https://www.westchem.org

    Department of Chemistry: https://chemistry.rice.edu/

    Wiess School of Natural Sciences: https://naturalsciences.rice.edu

    This news release can be found online at news.rice.edu.

    Follow Rice News and Media Relations via Twitter @RiceUNews.

    [ad_2]

    Rice University

    Source link

  • Organelles grow in random bursts

    Organelles grow in random bursts

    [ad_1]

    Newswise — Eukaryotic cells — the ones that make up most life as we know it, including all animals, plants and fungi — are highly structured objects.

    These cells assemble and maintain their own smaller, internal bits: the membrane-bound organelles like nuclei, which store genetic information, or mitochondria, which produce chemical energy. But much remains to be learned about how they organize themselves into these spatial compartments.

    Physicists at Washington University in St. Louis conducted new experiments that show that eukaryotic cells can robustly control average fluctuations in organelle size. By demonstrating that organelle sizes obey a universal scaling relationship that the scientists predict theoretically, their new framework suggests that organelles grow in random bursts from a limiting pool of building blocks.

    The study was published Jan. 6 in Physical Review Letters.

    “In our work, we suggest that the steps by which organelles are grown — far from being an orderly ‘brick-by-brick’ assembly — occur in stochastic bursts,” said Shankar Mukherji, assistant professor of physics in Arts & Sciences.

    “Such bursts fundamentally limit the precision with which organelle size is controlled but also maintain noise in organelle size within a narrow window,” Mukherji said. “Burstlike growth provides a general biophysical mechanism by which cells can maintain, on average, reliable yet plastic organelle sizes.”

    Organelles must be flexible enough to allow cells to grow or shrink them as environments demand. Still, the size of organelles must be maintained within certain limits. Biologists have previously identified certain molecular factors that regulate organelle sizes, but this study provides new insights into the quantitative principles underlying organelle size control.

    While this study used budding yeast as a model organism, the team is excited to explore how these assembly mechanisms are utilized across different species and cell types. Mukherji said that they plan to examine what these patterns of robustness can teach us about how to harness organelle assembly for bioengineering applications and how to spot defects in organelle biogenesis in the context of disease.

    “The pattern of organelle size robustness is shared between budding yeast and human iPS cells,” Mukherji said. “The underlying molecular mechanisms producing these bursts are yet to be fully elucidated and are likely to be organelle-specific and potentially species-specific.”

    Amiri KP, Kalish A and Mukherji S. Robustness and Universality in Organelle Size Control. Phys. Rev. Lett., Jan. 7, 2023. https://link.aps.org/doi/10.1103/PhysRevLett.130.018401

    Funding: This research was supported by the National Institutes of Health (NIH R35GM142704).

    [ad_2]

    Washington University in St. Louis

    Source link

  • Wayne State receives $1.7 million NIH award to understand and address ototoxic side effects of anti-cancer drug

    Wayne State receives $1.7 million NIH award to understand and address ototoxic side effects of anti-cancer drug

    [ad_1]

    Newswise — DETROIT – A Wayne State University researcher has received a $1.7 million, five-year award from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health for the study, “Targeting nitrative stress for treatment of cisplatin ototoxicity.” The research aims to address the critical gap that exists in understanding how nitrative stress caused by cisplatin treatment alters cochlear protein signaling causing apoptosis – or death of cells – in cisplatin-induced ototoxicity.

    The study, led by Samson Jamesdaniel, Ph.D., assistant professor of family medicine and public health in Wayne State’s School of Medicine and in the Institute of Environmental Health Sciences, stated that cisplatin and its analogs are prescribed to 10 to 20% of all cancer patients, causing hearing loss in up to 80% treated with the drug.

    “Cisplatin is a first-generation platinum-based anti-neoplastic drug that is the backbone of combination therapies to treat cancers of the bladder, cervix, lung [non-small cell], head and neck [squamous cell], testicle, mesothelium and some other solid tumors,” said Jamesdaniel. “The ototoxicity caused by treatments using cisplatin can significantly affect the quality of life in cancer survivors and lead to devastating consequences in children, with impacts on speech and language development, education and social integration.”

    Cisplatin-induced nitration and downregulation of LMO4, a molecular adaptor protein, appears to mediate its ototoxic effects. Jamesdaniel and his research team hope to better understand the characterization of the regulatory role of LMO4 nitration in cisplatin-mediated ototoxicity that may reveal the biological significance of this novel molecular mechanism.

    “The outcomes of this research will have important translational value by providing a strong foundation for identifying and developing novel therapeutic approaches to prevent the ototoxic effects of cisplatin,” said Timothy Stemmler, Ph.D., interim vice president for research at Wayne State. “Samson’s important research may lead to an effective intervention for cisplatin-induced ototoxicity that will improve lives of cancer survivors who have received this treatment.”

    The project number for this National Institutes of Health study is DC020299. To learn more, visit https://reporter.nih.gov/search/BwG81rDmTEKfb7HqEjgC-g/project-details/10587579

     

    About Wayne State University

    Wayne State University is one of the nation’s pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit research.wayne.edu.

    [ad_2]

    Wayne State University Division of Research

    Source link